楼主: 亚述学064
488 0

[英文文献] Innovation and uncertainty in the medical industry: Evidence from the case ... [推广有奖]

  • 0关注
  • 0粉丝

等待验证会员

学前班

0%

还不是VIP/贵宾

-

威望
0
论坛币
0 个
通用积分
0
学术水平
0 点
热心指数
0 点
信用等级
0 点
经验
10 点
帖子
0
精华
0
在线时间
0 小时
注册时间
2020-9-21
最后登录
2020-9-21

楼主
亚述学064 发表于 2005-6-17 19:23:15 |AI写论文

+2 论坛币
k人 参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群
赵安豆老师微信:zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

感谢您参与论坛问题回答

经管之家送您两个论坛币!

+2 论坛币
英文文献:Innovation and uncertainty in the medical industry: Evidence from the case of Myriad Genetics, Inc
英文文献作者:Stan Veuger,Jeffrey Clemens
英文文献摘要:
We describe the broad range of uncertainties faced by the developers of medical technologies. Empirically, we estimate the asset market incidence of two realizations of uncertainties we classify as within-market policy risks. The events we analyze concern the intellectual property of Myriad Genetics, Inc., an American molecular diagnostics firm. In July 2013, the Supreme Court invalidated several of Myriad's intellectual property claims. Subsequently, the Center for Medicare and Medicaid Services reevaluated the reimbursements it pays for the services at issue in this patent litigation. We estimate that these events substantially moved Myriad's market capitalization, by just under 25 percent in the case of the Supreme Court's decision and nearly 20 percent in the case of CMS's reimbursement rate re-determination. Myriad's exposure to the realization of these intellectual property risks reflects its unusually high reliance on revenues linked to the services at issue. We discuss the implications of these risks for the total volume of medical innovation and for its organization across firms.
二维码

扫码加我 拉你入群

请注明:姓名-公司-职位

以便审核进群资格,未注明则拒绝


您需要登录后才可以回帖 登录 | 我要注册

本版微信群
扫码
拉您进交流群
GMT+8, 2026-1-29 08:04